Anish Thomas, MBBS, M.D.

Lasker Clinical Research Scholar

Developmental Therapeutics Branch


Building 10 Room 4-5330
Bethesda, MD 20892


Research Topics

Our primary hypothesis is that a rational use of DNA damage response inhibitors can enhance replicative stress and augment efficacy of currently available therapies including chemotherapies and immunotherapies. The secondary hypothesis is that tumor targeted chemotherapy delivery could improve the tolerability of DNA damage response inhibitor-combinations. We now have 5 ongoing trials addressing these hypotheses. Our first trial, a phase I trial of an ATR kinase inhibitor and topotecan recently completed enrolment and we are now enrolling patients on phase II. Other ongoing trials involve combinations of PARP inhibitors with tumor targeted chemotherapy or immunotherapy.

The following trials are recruiting small cell cancer patients:

  1. A Phase II Trial of Topotecan plus VX970, an ATR Kinase Inhibitor (open also for extra-pulmonary small cell cancers)
  2. A phase II Trial of anti-PDL1 antibody durvalumab plus olaparib (SCLC cohort)
  3. A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers

The following trials are recruiting solid tumor patients who have previously been treated with chemotherapy:

  1. Phase I Study of a Combination of MM-398 and Veliparib in solid tumors
  2. A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
  3. The first-in-human phase I trial of PEN-866, PEN-866 in Patients With Advanced Solid Malignancies

Selected Recent Publications

  1. Thomas A, Pommier Y. Small cell lung cancer: time to revisit the DNA damaging chemotherapy strategy. Science Translational Medicine 2016; 8:346fs12. PMID: 27384345
  2. Thomas A, Redon C, Sciuto L, Padiernos E, Jiuping Ji, Lee M-J, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine C, Bates S, Kinders R, Steinberg S, Doroshow J, Aladjem M, Trepel J, Pommier Y. Phase I Study of ATR inhibitor M6620 in Combination with Topotecan in Patients with Advanced Solid tumors (in print Journal of Clinical Oncology).
  3. Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee M-J, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G. Sunitinib in patients with chemotherapy refractory thymoma and thymic carcinoma: an open label phase II trial. Lancet Oncology. 2015; 16:177-86. PMID: 25592632.
  4. Lopez-Chavez A, Thomas A (co-first author), Rajan A, Raffeld M, Morrow B, Kelly R,  Carter CA, Guha U, Killian K, Lau CL, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A,  Doyle A, Szabo E, Wang Y, Giaccone G. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: a biomarker derived multi-arm, multi-histology phase II “basket” trial. Journal of Clinical Oncology. 2015 Feb 9. PMID: 25667274.
  5. Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS One. 2016 Jun 13;11(6):e0156728. PMID: 27294665.
  6. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nature Reviews Clinical Oncology. 2015 May 12. PMID: 25963091.
  7. Thomas A, Chen Y, Steinberg S, Luo J, Giaccone G, Pastan I, Miettinen M, Hassan R. The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinoma. Oncotarget 2015;6:11694-703. PMID: 26028668.
  8. Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz RL, Steinberg SM, Trepel JB, Figg W, Schrump DS, Giaccone G. A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research. 2014; 20:5392-402. PMID: 25189481.


Anish Thomas, MD is a medical oncologist who specializes in the treatment of thoracic cancers. He received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, following which he completed residency in Internal Medicine from State University of New York Upstate Medical University, Syracuse. He trained in Medical Oncology and Hematology at the Medical Oncology Branch of National Cancer Institute and the National Heart Lung and Blood Institute, respectively.

Selected Publications

  1. Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y. Temozolomide in the Era of Precision Medicine. Cancer Res. 2017;77(4):823-826.

  2. Del Rivero J, Enewold L, Thomas A. Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Transl Lung Cancer Res. 2016;5(6):727-730.

  3. Thomas A, Chen Y, Berman A, Schrump DS, Giaccone G, Pastan I, Venzon DJ, Liewehr DJ, Steinberg SM, Miettinen M, Hassan R, Rajan A. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer. 2016;101:104-110.

  4. Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS One. 2016;11(6):e0156728.

  5. Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R. Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J Thorac Oncol. 2016;11(11):1993-2005.

This page was last updated on June 3rd, 2020